News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
TapImmune Inc. Signs License Agreement With Crucell N.V.
November 5, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BELLEVUE, Wash., Nov. 5, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Deals
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
October 2, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Foghorn lays off 40% of staff after Lilly collaboration ends
October 1, 2026
·
2 min read
·
Angela Gabriel
Manufacturing
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
October 1, 2026
·
2 min read
·
Nick Paul Taylor
Immunology and inflammation
Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
October 1, 2026
·
3 min read
·
Tristan Manalac
